<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04646707</url>
  </required_header>
  <id_info>
    <org_study_id>19-5818</org_study_id>
    <nct_id>NCT04646707</nct_id>
  </id_info>
  <brief_title>Effect of Erector Spinae (ESP) Block on Opioid Reduction and Enhanced Recovery After Posterior Cervical Spine Surgery</brief_title>
  <official_title>Effect of Erector Spinae (ESP) Block on Opioid Reduction and Enhanced Recovery After Posterior Cervical Spine Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients undergoing spine surgery frequently experience significant pain after surgery. This&#xD;
      can limit patient activity and hinder rehabilitation. If inadequately treated, severe pain&#xD;
      can result in emotional and psychological distress and ultimately impact long-term function,&#xD;
      and increase the risk of developing pain that lasts longer than six months associated with&#xD;
      depression, anxiety and disability.&#xD;
&#xD;
      More specifically, Erector Spinae Plane (ESP) block is a recently described plane block&#xD;
      designed to block the dorsal and ventral rami of the thoracic spinal nerves. It has shown to&#xD;
      be an effective modality for postoperative pain management as a part of multimodal analgesia&#xD;
      in spinal surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing spine surgery frequently experience significant pain after surgery.&#xD;
      Currently, standard management of acute pain after surgery consists mainly of systemic opioid&#xD;
      narcotics and nonsteroidal anti-inflammatory drugs (NSAIDs). Generally, opiates and NSAIDs&#xD;
      are not completely effective at managing pain, and they carry significant risk of addiction&#xD;
      and overdose, particularly with prolonged or increased dosing. The concept of multimodal or&#xD;
      ''balanced'' analgesia is rapidly becoming the 'standard of care' for preventing&#xD;
      post-operative pain. It consists of the use of combinations of analgesics of different&#xD;
      classes with different sites of action in an attempt to provide superior pain relief with&#xD;
      reduced analgesic related side effects. Local anesthetic injection to block specific nerves&#xD;
      has been widely recognized as a useful adjunct in a multimodal approach to postoperative pain&#xD;
      management.&#xD;
&#xD;
      Erector Spinae Plane (ESP) block is a recently described plane block designed to block the&#xD;
      dorsal and ventral rami of the thoracic spinal nerves. It has shown to be an effective&#xD;
      modality for postoperative pain management as a part of multimodal analgesia in spinal&#xD;
      surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 17, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a double blind, randomized control clinical trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Recovery 40 Questionnaire</measure>
    <time_frame>24 hours after surgery.</time_frame>
    <description>the global Quality of Recovery-40 aggregate score is a scale from (1 to 5, where: 1 = very poor and 5 = excellent)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>2 weeks and one month</time_frame>
    <description>is a visual analog scale from (1 to 10, where: 1 is the mildest and 10 the worst possible)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioids consumption</measure>
    <time_frame>2 weeks and one month</time_frame>
    <description>Patient Opioid/Non-Opioid Pain Medications Diary Card After Surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Postoperative</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bilateral ESP block at T1 level with 20 ml of 1:1 mixture (2% Lidocaine: 0.5% bupivacaine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Bilateral ESP block at T1 level with 20 ml of 0.9% normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erector Spinae (ESP) Block with Lidocaine/Bupivacaine</intervention_name>
    <description>Bilateral ESP block at T1 level with 20 ml of 1:1 mixture (2% Lidocaine: 0.5% bupivacaine)</description>
    <arm_group_label>Study group</arm_group_label>
    <other_name>Study group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erector Spinae (ESP) Block with placebo</intervention_name>
    <description>Bilateral ESP block at T1 level with 20 ml of 0.9% normal saline</description>
    <arm_group_label>Placebo Group</arm_group_label>
    <other_name>Placebo group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All adult patients aged 18-80 years with ASA class I - III undergoing posterior cervical&#xD;
        (C3-T2) decompression and instrumented fusion for cervical stenosis in prone position.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. In patients who are allergic to local anesthetics.&#xD;
&#xD;
          2. ASA IV patients&#xD;
&#xD;
          3. Lack of informed consent&#xD;
&#xD;
          4. Pregnant patient.&#xD;
&#xD;
          5. Fracture cervical spine&#xD;
&#xD;
          6. Extradural or intradural cervical tumors&#xD;
&#xD;
          7. Surgery of C1 and C2 spine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Dinsmore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Dinsmore, MD</last_name>
    <phone>416 603 5800</phone>
    <phone_ext>2269</phone_ext>
    <email>michael.dinsmore@uhn.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ki Jinn Chin, MD</last_name>
    <phone>416 603 5800</phone>
    <phone_ext>2269</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Toronto Western Hospital?UHN</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Dinsmore, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Emad Al Azazi, MD</last_name>
      <phone>416-603-5800</phone>
      <phone_ext>6237</phone_ext>
      <email>emad.alazazi@uhnresearch.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 5, 2019</study_first_submitted>
  <study_first_submitted_qc>November 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2020</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Michael Dinsmore</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Opioid</keyword>
  <keyword>Reduction</keyword>
  <keyword>Enhanced</keyword>
  <keyword>Postoperative</keyword>
  <keyword>Recovery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

